Phase I, Double-Blind, Randomized, Placebo-Controlled Trial to Examine the Safety, Tolerability and Plasma Pharmacokinetics of Ascending Oral Doses of TMC435350 After Single and Repeated Dosing in Healthy Japanese Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2009
At a glance
- Drugs Simeprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 29 Jan 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
- 29 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Nov 2008 Status changed from recruiting to active, no longer recruiting as reported by Clinicaltrials.gov.